Saturday 21 December 2024

The Pharma Letter Podcast — Episode 18 — Focus on rare liver diseases, with Albireo CEO Ron Cooper

Pharmaceutical
Simon Wentworth
31 October 2022
episode18-big

More on this story...

Biotechnology
Albireo shares rocket as study sets up second Bylvay approval
12 October 2022
Biotechnology
NICE backs NHS use of Albireo's Bylvay for all PFIC types
22 February 2022
Biotechnology
Albireo's Bylvay gets FDA green light for PFIC
21 July 2021
Pharmaceutical
Evaluate expects Roche to lead the way in steady pharma growth to 2028
21 October 2022


Companies featured in this story

More ones to watch >


Today's issue

Neurocrine Biosciences launches Crenessity in USA
Pharmaceutical
Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Biotechnology
Epitopea teams up with Genevant in $124 million deal
20 December 2024
Biotechnology
Mixed results for GSK’s Zejula/Jemperli combo
20 December 2024
Biotechnology
Regeneron advances anticoagulant antibody program
20 December 2024
Pharmaceutical
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Biotechnology
Astellas partners with Sangamo on cutting-edge gene therapy
20 December 2024
Biotechnology
Novartis to shut MorphSys sites amid pelabresib delay
20 December 2024

Company Spotlight

Australian regenerative medicine company Mesoblast (ASX: MSB) is developing biotherapeutics based on its proprietary cell-based technologies.




More Features in Pharmaceutical

Neurocrine Biosciences launches Crenessity in USA
20 December 2024
Zealand blindsided by FDA rejection of glepaglutide
20 December 2024
Novo Nordisk touts CagriSema success, but results miss expectations
20 December 2024
FDA approves Ionis’ Tryngolza
20 December 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze